Prognostic significance of cyclooxygenase-2 and response to chemotherapy in invasive ductal breast carcinoma patients by real time surface plasmon resonance analysis

DNA and Cell Biology

Volumn 30, Issue 10, 2011, Pages 801-807

  Singh, Abhay Kumar ^a   Parshad, Rajinder ^a   Pasi, Shweta ^a   Madhavan, Thirumurthy ^a   Das, Satya N ^a   Mishra, Biswajit ^a   Gill, Kamaldeep ^a   Dalal, Krishna ^a   Dey, Sharmistha ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER PATIENT; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SERUM; SURFACE PLASMON RESONANCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CARCINOMA, DUCTAL, BREAST; CHEMOTHERAPY, ADJUVANT; CYCLOOXYGENASE 2; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; PROGNOSIS; SURFACE PLASMON RESONANCE; TUMOR MARKERS, BIOLOGICAL;

EID: 80053476831     PISSN: 10445498     EISSN: 15577430     Source Type: Journal    
DOI: 10.1089/dna.2011.1215     Document Type: Article

References (40)

1. Andrew, T.C. (2009). COX-2 expression in adenoma: an imperfect marker for chemoprevention. Int J Gastroenterol Hepatol 59, 568-569.
2. Andrew, T.C., Shuji, O., Charles, S., and Fuchs, M.D. (2007). Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of COX-2. N Engl J Med 356, 2131-2142.
3. Arun, B., and Goss, P. (2004). The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol 31, 22-29. (Pubitemid 38879411)
4. Basu, G.D., Pathangey, L.B., Tinder, T.L., Gendler, S.J., and Mukherjee, P. (2005). Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res 7, R422-R435.
5. Berg, J.W., and Robbins, G.F. (1966). Factors influencing short and long term survival of breast cancer patients. Surg Gynecol Obstet 122, 1311-1316.
6. Brinton, L.A., Williams, R.R., Hoover, R.N., Stegens, N.L., Feinleib, M., and Fraumeni, J.F. (1979). Breast cancer risk factors among screening program participants. J Natl Cancer Inst 62, 37-44. (Pubitemid 9083803)
7. Brueggemeier, R.W., Quinn, A.L., Parrett, M.L., Joarder, F.S., Harris, R.E., and Robertson, F.M. (1999). Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 140, 27-35. (Pubitemid 29251310)
8. Cejas, P., García-Cabezas, M.A., Casado, E., Barriuso, J., Fresno, J.A., Díaz, E., Belda-Iniesta, C., Castro, J., Espinosa, E., Zamora, P., Feliu, J., Redondo, A., Hardisson, D.A., and González-Baró n, M. (2005). Localisation of COX-2 protein is different in breast ductal carcinoma and adjacent non-tumour ductal epithelium. Clin Transl Oncol 7, 239-243.
9. Chen, A.Y., and Liu, L.F. (1994). DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 34, 191-218.
10. Chow, L.W.C., Loo, W.T.Y., and Toi, M. (2005). Current directions for COX-2 inhibition in breast cancer. Biomed. Pharmacother 59 Suppl 2, S281-S284.
11. Crawford, Y.G., Gauthier, M.L., Joubel, A., Mantei, K., Kozakiewicz, K., Afshari, C.A., and Tlsty, T.D. (2004). Histologically normal human mammary epithelia with silenced p16(INK4a) overexpress COX-2, promoting a premalignant program. Cancer Cell 5, 263-273. (Pubitemid 38402118)
12. Dannenberg, A.J., Lippman, S.M., Mann, J.R., Subbaramaiah, K., and DuBois, R.N. (2005). Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 23, 254-266. (Pubitemid 46206877)
13. Denkert, C., Winzer, K., and Hauptmann, S. (2004). Prognostic impact of cyclooxygenase-2 in breast cancer. Clin. Breast Cancer 4, 428-433. (Pubitemid 38443466)
14. Dutcher, J.P., Novik, Y., O'Boyle, K., Marcoullis, G., Secco, C., and Wiernik, P.H. (2000). 20th-century advances in drug therapy in oncology-Part. II. J Clin Pharmacol 40, 1079-1092.
15. Haertel-Wiesmann, M., Liang, Y., Fantl, W.J., and Williams, L.T. (2000). Regulation of cyclooxygenase-2 and periostin byWnt-3 in mousemammary epithelial cells. J. Biol. Chem275, 32046-32051.
16. Harris, R.E., Robertson, F.M., Abou-Issa, H.M., Farrar, W.B., and Brueggemeier, R. (1999). Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer. Med. Hypotheses 52, 291-292. (Pubitemid 29243566)
17. Herschman, H.R., Gilbert, R.S., Xie, W., Luner, S., and Reddy, S.T. (1995). The regulation and role of TIS10 prostaglandin synthase- 2. Adv. Prostaglandin Thromboxane Leukot Res 23, 23-28.
18. Howe, L.R., Subbaramaiah, K., Brown, A.M., and Dannenberg, A.J. (2001). Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr. Relat. Cancer 8, 97-114. (Pubitemid 32641352)
19. Hwang, D., Scollard, D., Byrne, J., and Levine, E. (1998). Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90, 455-460. (Pubitemid 28160637)
20. Jiang, W.G., Douglas-Jones, A., and Mansel, R.E. (2003). Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. Prostaglandins Leukot. Essent Fatty Acids 69, 275-281. (Pubitemid 37463809)
21. Kretschmann, E., and Raether, H. (1968). Radiative decay of nonradiative surface plasmons excited by light. Z Naturforsch 23, 2135-2136.
22. Lee, J.L.,Mukhtar, H., Bickers, D.R., Kopelovich, L., and Athar, M. (2003). Cyclooxygenases in the skin: pharmacological and toxicological implications. Toxicol Appl Pharmacol 192, 294-306. (Pubitemid 37311345)
23. Liu, X.H., and Rose, D.P. (1996). Differential expression and regulation of cyclooxygenase-1 and-2 in two human breast cancer cell lines. Cancer Res 56, 5125-5127.
24. McCarthy, K., Bustin, S.A., Ogunkolade, B., Khalaf, S., Laban, C.A., McVittie, C.J., Carpenter, R., and Jenkins, P.J. (2006). Cyclo-oxygenase-2 (COX-2) mRNA expression and hormone receptor status in breast cancer. Eur J Surg Oncol 32, 707-709. (Pubitemid 44275998)
25. Minghetti, L. (2004). Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 63, 901-910. (Pubitemid 39202493)
26. Nylander, C., Leidberg, B., and Lind, T. (1982). Gas-detection by means of surface-plasmon resonance. Sens Actuators 3, 79-88.
27. Otto, A. (1968). Excitation of surface plasma waves in silver by the method of frustrated total reflection. Z Phys 216, 398-410.
28. Queiroga, F.L., Alves, A., Pires, I., and Lopes, C. (2007). Expression of Cox-1 and Cox-2 in canine mammary tumours. J Comp Pathol 136, 177-185. (Pubitemid 46546139)
29. Rozenowicz, R.D., Santos, R.E., Silva, M.A., Rodrigues, F.F., Oliveira, A.L., Ulson, L.B., Oliveira, V.M., and Aoki, T. (2010). Cox-2 and its association with prognostic factors and response to primary chemotherapy in patients with breast cancer. Rev Col Bras Cir 37, 323-327.
30. Schrey, M.P., and Patel, K.V. (1995). Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators. Br J Cancer 72, 1412-1419.
31. Shen, J., Gammon, M.D., Terry, M.B., Teitelbaum, S.L., Neugut, A.I., and Santella, R.M. (2006). Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Res 8, R71.
32. Sheng, H., Williams, C.S., Shao, J., Liang, P., DuBois, R.N., and Beauchamp, R.D. (1998). Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway. J Biol Chem 273, 22120-22127. (Pubitemid 28405396)
33. Shim, V., Gauthier, M.L., Sudilovsky, D., Mantei, K., Chew, K.L., Moore, D.H., Cha, I., Tlsty, T.D., and Esserman, L.J. (2003). Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium. Cancer Res 63, 2347-2350. (Pubitemid 36605165)
34. Singh, B., and Lucci, A. (2002). Role of cyclooxygenase-2 in breast cancer. J Surg Res 108, 173-179. (Pubitemid 35373830)
35. Subbaramaiah, K., Telang, N., Ramonetti, J.T., Araki, R., DeVito, B., Weksler, B.B., and Dannenberg, A.J. (1996). Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res 56, 4424-4429. (Pubitemid 26330450)
36. Vadlamudi, R., Mandal, M., Adam, L., Steinbach, G., Mendelsohn, J., and Kumar, R. (1999). Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 18, 305-314. (Pubitemid 29060606)
37. Wang, D., Dubois, R.N.,(2004). Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol 31, 64-73. (Pubitemid 38543941)
38. Weiss, H.A., Brinton, L.A., Potischman, N.A., Brogan, D., Coates, R.J., Gammon, M.D., Malone, K.E., and Schoenberg, J.B. (1999). Breast cancer risk in young women and history of selected medical conditions. Int J Epidemiol 28, 816-823. (Pubitemid 29525019)
39. Xie, W., and Herschman, H.R. (1995). v-src induces prostaglandin synthase 2 gene expression by activation of the c-Jun N-terminal kinase and the c-Jun transcription factor. J Biol Chem 270, 27622-27628.
40. Zhao, X., Goswami, M., Pokhriyal, N., Ma, H., Du, H., Yao, J., Victor, T.A., Polyak, K., Sturgis, C.D., Band, H., and Band, V. (2008). Cyclooxygenase-2 expression during immortalization and breast cancer progression. Cancer Res 68, 467-475. (Pubitemid 351380073)